Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis

Circulation Research

Volumn 89, Issue 5, 2001, Pages 415-421

  Ni, Weihua ^a   Egashira, Kensuke ^a   Kataoka, Chu ^a   Kitamoto, Shiro ^a   Koyanagi, Masamichi ^a   Inoue, Shujiro ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Arteriosclerosis; Endothelium derived factors; Inflammation; Monocyte chemoattractant protein 1; Nitric oxide synthase

Indexed keywords

CERIVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; RHO FACTOR; STATINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ARTERIOSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HEART; INFLAMMATION; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 0035980169     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/hh1701.096614     Document Type: Article

References (37)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Current concepts in cardiovascular pathology: The role of LDL cholesterol in plaque rupture and stabilization
4. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
7. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
8. Beneficial effects of cholesterol-lowering therapy on the coronary endothetium in patients with coronary artery disease
9. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
10. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice
11. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats
12. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels
13. Atherosclerosis - An inflammatory disease
14. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylghtaryl coenzyme A reductase inhibitor, in rats
15. Postcolumn fluorometric detection system for liquid chromatographic analysis of amino and imino acids using o-phthalaldehyde/N-acetyl-L-cysteine reagent
16. An automated method for the simultaneous determination of pravastatin and its main metabolite in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry
17. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis
18. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis
19. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats
20. Specific receptor-guanine nucleotide binding protein interaction mediates the release of endothelium-derived relaxing factor
21. G-nitro-L-arginine methylester in canine blood in vitro
22. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia
23. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
24. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
25. Targeting Rho in cardiovascular disease
26. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kipl)
27. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats
28. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
29. Angiotensin II activates RhoA in cardiac myocytes: A critical role of RhoA in angiotensin II-induced premyofibril formation
30. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells
31. The cellular functions of small GTP-binding proteins
32. Neuroprotection mediated by changes in the endothelial actin cytoskeleton
33. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects
34. Biotransformation of cerivastatin in mice, rats, and dogs in vivo
35. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys
36. Long-term effects of pravastatin on plasma concentration of C-reactive protein
37. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys